Default company panoramic image

Neurotune AG

New hope for patients with fatal neuromuscular diseases such as SMA or ALS.

  • Stage Product In Development
  • Industry Biotechnology
  • Location 8048 Schlieren, ZH, Switzerland
  • Currency CHF
  • Founded February 2005
  • Employees 5
  • Website

Company Summary

Neurotune is a clinical stage, R&D focused biotech company. The focus is on the development of novel drugs for neuromuscular diseases (including sarcopenia), neuropatic pain and kidney diagnostic.


  • Default avatar
    Armin W. Mäder

    Armin Mäder held senior positions in biotech and medtech companies such as Institut Straumann AG. He was the CFO/COO of the biotech start-up company AC Immune SA in Lausanne, Switzerland. Armin Mäder started his professional career in the UBS Investment Bank where he has worked in business development and business management.

    Armin Mäder holds an M.B.A. from IMD and a PhD in Molecular Biology and Biophysics from ETH Zurich.

  • Default avatar
    Stefan Hettwer
    Head R&D

    Stefan has more than 10 years of experience in preclinical development of small molecule, protein drug candidates as well as diagnostic assays (ELISA). Prior to working for Neurotune AG that he joined in 2005, he drove the neurotrypsin/agrin research in Prionics as well as the University of Zurich.

    Stefan obtained his Doctorate in Biochemistry from the University of Cologne in 2001.

  • Default avatar
    Bruno Oesch

    Bruno Oesch initiated Neurotune as a spin-off from Prionics AG in 2005. Since the start of the company he served as the Chairman of the Board of directors. 2009/10 he also was CEO and currently acts as Chairman with a focus on BD&L.

    Previously, Bruno also co-founded Prionics. He graduated from the ETH Zurich with a Master's degree in Natural Sciences and obtained his PhD from the University of Zurich in 1987.


  • Default avatar
    Badertscher Rechtsanwälte, Zürich, Switzerland
    Default avatar
    BDO AG (auditor)

Previous Investors

  • Default avatar
    Private investors